Vaxart, Inc., a biotechnology company based in the US with a symbol ‘VXRT’, has a market cap of 128 million dollars as of 3 February 2023. The market capitalization for this company has been fluctuating over the past few days. On 1 February 2023, it was recorded at 143.06 million dollars, decreasing to 144.37 million dollars on 2 February and then dropping further to 141.74 million dollars on 3 February. Last year, Vaxart’s market cap was 5.43 dollars per share, peaking from its lowest point of 0.73 dollar per share in 2020.
The volume of shares traded for Vaxart has also been variable in recent times. For instance, on 3 February it was recorded at 1123 thousand shares, while the average volume traded over the last fifty trading days stands at 2944 thousand shares. Furthermore, the previous closing price was 0.9413 dollar per share and its current value is 0.9771 dollar per share with an increase of 3.8033 percent over the same period of time according to NASDAQ exchange rates data available on that day.
Finally, given that Vaxart’s earnings per share (EPS) is -0.641 dollar per share and its Price-Earnings ratio (P/E) is not available; we can conclude that Vaxart’s financial situation is relatively weak and investors are not particularly optimistic about long term investments in this company at present time due to lack of information about its future performance and expected returns on investments made into it by shareholders or potential investors alike
